US 12,357,611 B2
Sulcardine administration for treatment of acute atrial fibrillation
Suzanne J. Romano, Carlsbad, CA (US); and Gary T. Elliott, Windsor, CO (US)
Assigned to Huyabio International, LLC, San Diego, CA (US)
Filed by HUYABIO International, LLC, San Diego, CA (US)
Filed on Dec. 19, 2023, as Appl. No. 18/545,558.
Application 18/545,558 is a continuation of application No. 17/750,944, filed on May 23, 2022, granted, now 11,883,380, issued on Jan. 30, 2024.
Application 17/750,944 is a continuation of application No. 16/712,677, filed on Dec. 12, 2019, granted, now 11,364,223, issued on Jun. 21, 2022.
Claims priority of provisional application 62/858,324, filed on Jun. 6, 2019.
Claims priority of provisional application 62/779,056, filed on Dec. 13, 2018.
Prior Publication US 2024/0115548 A1, Apr. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4025 (2006.01); A61P 9/06 (2006.01)
CPC A61K 31/4025 (2013.01) [A61P 9/06 (2018.01)] 20 Claims
 
1. A method of treating an arrhythmia in a human subject, comprising administering to the human subject a pharmaceutical composition comprising a pharmaceutically acceptable dose of N-[4-hydroxy-3,5-bis(1-pyrrolidinylmethyl)benzyl]-4-methoxybenzenesulfonamide (Sulcardine) or a pharmaceutically acceptable salt thereof, wherein administering the composition to the human subject produces in the human subject pan-ECG parameter changes comprising an increase in QTcF and a decrease in JTp.